Lexicon Pharmaceuticals Inc (NASDAQ:LXRX)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease.

LXRX News and Commentary

Caps

How do you think LXRX will perform against the market?

Add Stock to CAPS Watchlist

All Players

258 Outperform
46 Underperform
 

All-Star Players

47 Outperform
9 Underperform
 

Wall Street

5 Outperform
1 Underperform
 

Top LXRX Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

zzlangerhans (99.81)
Submitted February 03, 2014

Lexicon stock is declining but I think it's mostly a tidal effects related to a market correction and weakness in speculative sectors like s,mall cap biopharma. I've made my issues with Lexicon's valuation clear and the street as responded over and… More

Brosan (< 20)
Submitted January 28, 2011

With more less than 80c per share available in cash, LXRX will have a very hard time to keep their heads above water. The me-too compound, LX4211, seems to be stuck in the ground due to the lack of interest in the pharma community. Even it finds a… More

LXRX VS S&P 500 (SPY)

Fools bullish on LXRX are also bullish on:

Recent Community Commentary

Read the most recent pitches from players about LXRX.

Recs

0
Member Avatar NHWeston102 (60.66) Submitted: 4/1/2016 9:28:44 AM : Outperform Start Price: $11.96 LXRX Score: -18.47

A variety of breakthrough drugs which will likely clear FDA this year.

Recs

0
Member Avatar manirg (< 20) Submitted: 8/28/2015 10:19:46 PM : Outperform Start Price: $11.94 LXRX Score: -22.43

Fool Sean's pick & I like it too!!

Recs

0
Member Avatar LMNOPQRStallion (97.00) Submitted: 8/20/2015 12:45:43 AM : Outperform Start Price: $7.77 LXRX Score: +41.50

Recent LX1032 phase 3 data likely leads to approval, and to robust launch due to pent-up demand and complete lack of effective therapy for patients refractory to SSA. Incidence rate and OS for carcinoid syndrome both increasing, $450 mln peak sales conservatively with full US and Japan marketing rights retained, as well as royalties from French partner Ipsen.

As of 8-19-15, opportunistic entry/addition point for short-term trade or long-term position after recent pullback despite significant de-risking event in phase 3 read-out. $1.1 bin now quite undervalued given risk:reward. Call $30 PT EOY 2016.

Leaderboard

Find the members with the highest scoring picks in LXRX.

Score Leader

sglubis2

sglubis2 (95.98) Score: +173.01

The Score Leader is the player with the highest score across all their picks in LXRX.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
sglubis2 95.98 9/16/2009 Underperform 3M $19.60 -36.79% +136.22% +173.01 0 Comment
chuckyd5737 < 20 9/18/2006 Underperform 3M $26.39 -53.05% +100.67% +153.72 0 Comment
stockjock11 < 20 1/20/2010 Underperform NS $16.94 -26.86% +119.65% +146.51 0 Comment
radmtom < 20 1/20/2010 Underperform 1Y $16.73 -25.94% +119.67% +145.62 0 Comment
IceNineTX < 20 11/27/2006 Underperform 3M $27.02 -54.15% +88.84% +142.99 1 Comment
SLTiger < 20 1/3/2007 Underperform NS $25.41 -51.24% +86.12% +137.36 0 Comment
Forestboy 99.49 1/22/2007 Underperform NS $23.10 -46.36% +85.06% +131.42 0 Comment
dvddanhype 73.97 4/20/2007 Underperform NS $25.76 -51.90% +77.92% +129.82 0 Comment
longtermgrowth09 < 20 12/17/2009 Underperform 5Y $12.60 -1.67% +125.29% +126.96 0 Comment
str8nuts < 20 1/19/2010 Underperform 3W $13.65 -9.23% +116.79% +126.02 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackPoisedTo < 20 7/20/2012 Underperform 5Y $19.46 -36.33% +82.14% +118.47 0 Comment
TrackPoisedTo < 20 2/8/2012 Underperform 5Y $12.04 +65.70% +2.05% -63.64 7/19/2012 @ $19.95 0 Comment
TrackNeedham 91.33 5/27/2011 Outperform NS $10.64 +16.45% +87.03% -70.58 0 Comment
TrackWedbush 86.75 4/26/2011 Outperform NS $11.97 +3.51% +86.08% -82.57 0 Comment
TrackWayneRogers 59.77 1/7/2011 Outperform 3M $14.00 -11.50% +96.19% -107.69 0 Comment
TrackZacks < 20 10/21/2008 Outperform 3M $10.99 -18.47% +14.04% -32.51 7/13/2010 @ $8.96 1 Comment
TrackZacks < 20 5/1/2008 Outperform 3M $14.70 -32.38% -29.98% -2.40 10/20/2008 @ $9.94 1 Comment
TrackEveillard 95.94 12/31/2007 Outperform NS $21.21 -41.58% +77.80% -119.39 1 Comment
TrackPZK < 20 8/7/2007 Outperform NS $21.77 -48.87% -6.60% -42.28 4/17/2012 @ $11.13 0 Comment
TrackBofASec 96.11 5/15/2007 Outperform NS $23.66 -47.63% +74.99% -122.63 0 Comment
TrackPiperJaff 86.84 2/22/2007 Outperform NS $29.05 -62.41% -10.81% -51.60 3/7/2008 @ $10.92 0 Comment
TrackRBCCapMkts 88.19 1/30/2007 Outperform NS $25.97 0% +8.01% -8.01 10/31/2007 @ $25.97 0 Comment

Featured Broker Partners